Dr Reddy’s gets nod from DCGI for Sputnik V vaccine trial
Dr Reddy’s Laboratories, a leading multinational pharmaceutical company and Russian Direct Investment Fund (RDIF) announced on Saturday that it has received approval to conduct an adaptive phase 2/3 human clinical trial for the Sputnik V vaccine in India from Drug Control General of India (DCGI). Reacting to the news, its share on Monday gained almost 2 per cent during the early trading session on BSE.
Dr Reddy’s and RDIF entered into a partnership in early September 2020 to conduct clinical trials and distribution of Sputnik V vaccine in India and as a part of it, RDIF would be delivering 100 million doses of the vaccine to Dr Reddy’s after receiving regulatory approval in India.
Sputnik V vaccine is the world’s first registered vaccine against COVID-19 based on the human adenoviral vectors platform, which was developed on August 11, 2020, by Gamaleya National Research Institute of Epidemiology & Microbiology and was registered by the Ministry of Health (Russia).
At 11.03 am on Monday, Dr Reddy’s was trading 0.17 per cent down at Rs 5,073.7. The share has an intraday high of Rs 5,213.5 and an intraday low of Rs 5,070.45. In comparison, S&P BSE Healthcare index was trading 0.58 per cent down.